SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is seeing intense retail activity fueled by anticipation of a potential buyout and upcoming clinical data, creating a significant short squeeze setup that the community is actively tracking. Investors are discussing the high short interest and lack of available shares to borrow, while debating whether current price levels are justified by potential long-term breakthroughs in oncology.

Comcast Corp. engages in the provision of video, Internet, and phone services. It operates through the following segments: Residential Connectivity and Platforms, Business Services Connectivity, Media, Studios, and Theme Parks. The Residential Connectivity and Platforms segment consists of residential broadband and wireless services and Sky-branded entertainment television networks and advertising. The Business Service Connectivity segment offers broadband, wireline voice and wireless services through small to medium customers and large enterprises through the HFC network. The Media segment consists of NBCUniversal’s television and streaming platforms, including national, regional, and international cable networks. The Studios segment focuses on NBCUniversal’s film and television studio production and distribution operations. The Theme Parks segment operates Universal theme parks in Orlando, Florida, Hollywood, California, Osaka, Japan, and Beijing, China. The company was founded by Ralph Roberts in 1963 and is headquartered in Philadelphia, PA.

Comcast Corp - Ordinary Shares - Class A

Comcast Corp

Comcast is seeing heightened activity as investors weigh its deep valuation and strong free cash flow against persistent concerns over broadband subscriber losses and intense competition from satellite internet. The community remains divided, with some betting on a rebound driven by theme park growth, sports broadcasting, and dividend reliability, while others express frustration over the stock's long-term stagnant price performance.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is seeing significant market interest as investors react to the potential win of a major Japanese government J-LEO contract and the company's competitive positioning against Starlink. The community is actively discussing a possible short squeeze and the strategic implications of partnerships as they monitor institutional positioning and upcoming launch milestones.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is experiencing significant upward momentum and trending interest as retail investors pile into the stock, fueled by intense speculation regarding its potential inclusion in the Russell 1000 index. Community discourse remains highly active, with long-term shareholders highlighting anticipation for upcoming clinical and commercial catalysts, while simultaneously clashing with short sellers over the stock's future direction.

Iridium Communications, Inc. operates as a commercial provider of communications services offering true global coverage, connecting people, organizations and assets to and from anywhere, in real time. It offers its services to businesses, the U.S. and foreign governments, non-governmental organizations, and consumers via satellite network, which has an architecture of operational satellites with in-orbit spares and related ground infrastructure. Its products include personal communicators, messengers, and trackers, satellite phones, push-to-talk-devices, broadband terminals, midband terminals, external antennas, docking stations, apps, accessories and developer tools & resources. The company was founded in 2000 and is headquartered in McLean, VA.

Iridium Communications Inc

Iridium Communications is currently the subject of intense buyout speculation, with market chatter linking the company to potential acquirers like SpaceX or Amazon as investors highlight the strategic value of its globally harmonized L-band spectrum. While some community members argue that Iridiums critical role in government and defense infrastructure makes an outright sale unlikely, the stock remains a central focus for traders betting on further consolidation in the satellite sector.

Charter Communications, Inc. engages in providing broadband communications services. Its services include Spectrum TV, Spectrum Internet, and Spectrum Voice. It offers business-to-business Internet access, data networking, business telephone, video and music entertainment services, and wireless backhaul. Its advertising sales division, Spectrum Reach, offers local, regional, and national businesses the opportunity to advertise in individual and multiple service areas on cable television networks and advanced advertising platforms. The company was founded in 1993 and is headquartered in Stamford, CT.

Charter Communications Inc. - Ordinary Shares - Class A

Charter Communications is seeing heightened activity as community members debate its aggressive share buyback strategy, institutional ownership levels, and a potential partnership with SpaceX to enhance mobile offerings. While some investors view the stock's significant decline as an undervalued entry point, others remain skeptical, focusing on the company's substantial debt load and stiff competition from satellite internet providers.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is attracting significant attention as investors react to the company's strategic pivot to discontinue internal discovery programs and close its Alabama facility in favor of an external innovation model. The community is actively debating the implications of this cost-cutting measure, with many speculating that cleaning up the balance sheet could position the company as a more attractive acquisition target.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as investors debate its valuation, specifically questioning whether it should be viewed as a traditional social media platform or a high-growth data infrastructure play for AI training. Community sentiment is deeply divided, with traders focused on structural support levels and potential short-term volatility, while others speculate on long-term monetization potential through data licensing deals.

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Viridian Therapeutics is capturing significant market attention following the FDA approval of Lumvoa for thyroid eye disease, with the community actively debating the drug's commercial potential against established competitors like Tepezza. Discussion is heavily focused on the company's immediate launch strategy, the significance of the broad label covering both active and chronic disease, and whether current valuation levels account for this pivotal commercial milestone.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently in the spotlight following the announcement of three new NASA launch contracts, which reinforces its credibility as a reliable, institutional-grade partner in the space infrastructure sector. Despite recent volatility and broader sector pressure linked to SpaceX liquidity dynamics, the community remains intensely focused on the company's long-term execution, backlog growth, and the upcoming Neutron rocket development as key catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$RUBI Outlook for the coming days: Due to the extreme dilution spiral (a &quot;death spiral&quot; driven by continuous capital increases and warrant exercises), the downward trend is highly likely to continue. There is a very high risk that the share price will gradually slide back toward the $1 mark over the coming weeks.

StockTwits Web

Rubico Inc.

 Outlook for the coming days: Due to the extreme dilution spiral (a "death spiral" driven by continuous capital increases and warrant exercises), the downward trend is highly likely to continue. There is a very high risk that the share price will gradually slide back toward the $1 mark over the coming weeks.

Joyce

@sweet_Journey looks like another death spirall is looming with further dilution, there is no come-back in foresight unless they buy back the shares!

 looks like another death spirall is looming with further dilution, there is no come-back in foresight unless they buy back the shares!